Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stock Scan April 2018: Pharma's Fizz Falls Flat

Executive Summary

In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.

You may also be interested in...



Takeda, Shire Finally Seal £46bn Deal

Persistence pays off for Takeda as it reaches a confirmed deal for the acquisition of Shire after a dogged pursuit, paving the way for the largest ever M&A transaction both in the Japanese pharma sector and by any Japanese company of an overseas target.

Stock Scan Q1 2018: A Slump And A Proper Correction

The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.

Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy

Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors Bristol and Roche, which will be presenting data for combinations in lung cancer at the American Association of Clinical Research meeting in April.

Related Content

Related Companies

UsernamePublicRestriction

Register

SC123015

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel